JAK2 and essential thrombocythemia: From a molecular standpoint, our cohort showed distributions broadly consistent with previously reported MPN series: JAK2 V617F mutations were highly prevalent in PV and present in a substantial proportion of ET vases, whereas CALR and MPL mutations were restricted to ET [13, 14].